Howland Capital Management LLC Sells 2,153 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Howland Capital Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,086 shares of the biopharmaceutical company’s stock after selling 2,153 shares during the period. Howland Capital Management LLC’s holdings in Gilead Sciences were worth $1,209,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC acquired a new stake in Gilead Sciences in the third quarter valued at about $25,000. YANKCOM Partnership acquired a new stake in Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at about $29,000. Finally, Valued Wealth Advisors LLC boosted its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 2.0 %

GILD stock opened at $96.04 on Friday. The stock’s fifty day simple moving average is $93.04 and its two-hundred day simple moving average is $86.65. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The stock has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the firm earned $2.29 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 572,824 shares of company stock valued at $53,611,715. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Piper Sandler lifted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.